Wells Fargo
PTGX icon

Wells Fargo’s Protagonist Therapeutics PTGX Stock Holding History

Wells Fargo’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.17M Sell
30,072
-41,573
-58% -$3.68M ﹤0.01% 2932
2025
Q4 		$6.26M Buy
71,645
+23,851
+50% +$1.95M ﹤0.01% 2456
2025
Q3 		$3.17M Buy
47,794
+6,107
+15% +$347K ﹤0.01% 2964
2025
Q2 		$2.3M Buy
41,687
+1,878
+5% +$90.1K ﹤0.01% 3123
2025
Q1 		$1.93M Buy
39,809
+1,013
+3% +$42.4K ﹤0.01% 3186
2024
Q4 		$1.5M Buy
38,796
+9,423
+32% +$411K ﹤0.01% 3413
2024
Q3 		$1.32M Sell
29,373
-817
-3% -$33K ﹤0.01% 3358
2024
Q2 		$1.05M Buy
30,190
+397
+1% +$11.6K ﹤0.01% 3463
2024
Q1 		$862K Buy
29,793
+13,636
+84% +$371K ﹤0.01% 3553
2023
Q4 		$370K Sell
16,157
-60,407
-79% -$1.06M ﹤0.01% 4067
2023
Q3 		$1.28M Buy
76,564
+5,513
+8% +$107K ﹤0.01% 3145
2023
Q2 		$1.96M Buy
71,051
+37,087
+109% +$928K ﹤0.01% 2933
2023
Q1 		$781K Buy
33,964
+33,927
+91,695% +$570K ﹤0.01% 3552
2022
Q4 		$404 Sell
37
-2,307
-98% -$19.5K ﹤0.01% 6440
2022
Q3 		$19K Sell
2,344
-3,281
-58% -$31K ﹤0.01% 5430
2022
Q2 		$44K Sell
5,625
-20,394
-78% -$247K ﹤0.01% 5086
2022
Q1 		$616K Sell
26,019
-14,339
-36% -$404K ﹤0.01% 4260
2021
Q4 		$1.38M Sell
40,358
-18,371
-31% -$581K ﹤0.01% 3836
2021
Q3 		$1.04M Buy
58,729
+28,711
+96% +$1.22M ﹤0.01% 4203
2021
Q2 		$1.35M Sell
30,018
-8,417
-22% -$278K ﹤0.01% 4008
2021
Q1 		$995K Sell
38,435
-35,096
-48% -$888K ﹤0.01% 4253
2020
Q4 		$1.48M Buy
73,531
+47,287
+180% +$1.02M ﹤0.01% 3718
2020
Q3 		$514K Buy
26,244
+11,275
+75% +$212K ﹤0.01% 4314
2020
Q2 		$265K Sell
14,969
-33,576
-69% -$421K ﹤0.01% 4742
2020
Q1 		$343K Buy
48,545
+15,067
+45% +$113K ﹤0.01% 4321
2019
Q4 		$237K Buy
33,478
+7,504
+29% +$74.5K ﹤0.01% 4845
2019
Q3 		$312K Buy
25,974
+5,421
+26% +$68.3K ﹤0.01% 4698
2019
Q2 		$248K Buy
20,553
+4,224
+26% +$46.7K ﹤0.01% 4849
2019
Q1 		$205K Sell
16,329
-2,016
-11% -$17.8K ﹤0.01% 4811
2018
Q4 		$123K Buy
18,345
+5,744
+46% +$45.6K ﹤0.01% 5189
2018
Q3 		$130K Sell
12,601
-604
-5% -$5.2K ﹤0.01% 5232
2018
Q2 		$89K Buy
13,205
+4,660
+55% +$35.8K ﹤0.01% 5424
2018
Q1 		$73K Buy
8,545
+3,045
+55% +$57.4K ﹤0.01% 5434
2017
Q4 		$115K Sell
5,500
-4,065
-42% -$72.1K ﹤0.01% 5245
2017
Q3 		$169K Buy
9,565
+3,617
+61% +$50.1K ﹤0.01% 5003
2017
Q2 		$67K Buy
5,948
+729
+14% +$7.79K ﹤0.01% 5319
2017
Q1 		$67K Hold
5,219
– – ﹤0.01% 5353
2016
Q4 		$115K Buy
+5,219
New +$116K ﹤0.01% 5080

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Wells Fargo's PTGX Position: Q1 2026 in Review

Wells Fargo reduced its Protagonist Therapeutics (PTGX) stake by 58% in Q1 2026, selling an estimated $3.68M and leaving 30,072 shares worth $3.17M. The position accounts for ﹤0.01% of the portfolio, ranked #2932.

Wells Fargo first reported a position in PTGX in Q4 2016 and has held it in 38 quarters since. The position peaked at $6.26M in Q4 2025. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Wells Fargo held 30,072 shares of Protagonist Therapeutics worth $3.17M as of Q1 2026.
  • Wells Fargo sold 41,573 Protagonist Therapeutics shares in Q1 2026, an estimated $3.68M.
  • Protagonist Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #2932 holding.
  • Wells Fargo first reported a position in Protagonist Therapeutics in Q4 2016 and has held it in 38 quarters since.
  • Wells Fargo's Protagonist Therapeutics position peaked at $6.26M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.